BACKGROUND: Often, patients with chronic kidney disease are reported to be unaware of it. We prospectively evaluated the association between awareness of kidney disease to end-stage renal disease and mortality. METHODS: We utilized 2000-2009 data from the National Kidney Foundation's Kidney Early Evaluation Program. Mortality was determined by cross reference to the Social Security Administration Death Master File and development of end stage by cross reference with the United States Renal Data System. RESULTS: Of 109,285 participants, 28,244 (26%) had chronic kidney disease defined by albuminuria or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2). Only 9% (n=2660) reported being aware of kidney disease. Compared with those who were not aware, participants aware of chronic kidney disease had lower eGFR (49 vs 62 mL/min/1.73 m(2)) and a higher prevalence of albuminuria (52% vs. 46%), diabetes (47% vs 42%), cardiovascular disease (43% vs 28%), and cancer (23% vs 14%). Over 8.5 years of follow-up, aware participants compared with those unaware had a lower rate of survival for end stage (83% and 96%) and mortality (78% vs 81%), P <.001. After adjustment for demographics, socioeconomic factors, comorbidity, and severity of kidney disease, aware participants continued to demonstrate an increased risk for end-stage renal disease (hazard ratio 1.37; 95% confidence interval, 1.07-1.75; P <.0123) and mortality (hazard ratio 1.27; 95% confidence interval, 1.07-1.52; P <.0077) relative to unaware participants with chronic kidney disease. CONCLUSIONS: Among patients identified as having chronic kidney disease at a health screening, only a small proportion had been made aware of their diagnosis previously by clinicians. This subgroup was at a disproportionately high risk for mortality and end-stage renal disease. Published by Elsevier Inc.
BACKGROUND: Often, patients with chronic kidney disease are reported to be unaware of it. We prospectively evaluated the association between awareness of kidney disease to end-stage renal disease and mortality. METHODS: We utilized 2000-2009 data from the National Kidney Foundation's Kidney Early Evaluation Program. Mortality was determined by cross reference to the Social Security Administration Death Master File and development of end stage by cross reference with the United States Renal Data System. RESULTS: Of 109,285 participants, 28,244 (26%) had chronic kidney disease defined by albuminuria or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2). Only 9% (n=2660) reported being aware of kidney disease. Compared with those who were not aware, participants aware of chronic kidney disease had lower eGFR (49 vs 62 mL/min/1.73 m(2)) and a higher prevalence of albuminuria (52% vs. 46%), diabetes (47% vs 42%), cardiovascular disease (43% vs 28%), and cancer (23% vs 14%). Over 8.5 years of follow-up, aware participants compared with those unaware had a lower rate of survival for end stage (83% and 96%) and mortality (78% vs 81%), P <.001. After adjustment for demographics, socioeconomic factors, comorbidity, and severity of kidney disease, aware participants continued to demonstrate an increased risk for end-stage renal disease (hazard ratio 1.37; 95% confidence interval, 1.07-1.75; P <.0123) and mortality (hazard ratio 1.27; 95% confidence interval, 1.07-1.52; P <.0077) relative to unaware participants with chronic kidney disease. CONCLUSIONS: Among patients identified as having chronic kidney disease at a health screening, only a small proportion had been made aware of their diagnosis previously by clinicians. This subgroup was at a disproportionately high risk for mortality and end-stage renal disease. Published by Elsevier Inc.
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Delphine S Tuot; Laura C Plantinga; Chi-Yuan Hsu; Regina Jordan; Nilka Ríos Burrows; Elizabeth Hedgeman; Jerry Yee; Rajiv Saran; Neil R Powe Journal: Clin J Am Soc Nephrol Date: 2011-07-22 Impact factor: 8.237
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Wendy Weinstock Brown; Rosalind M Peters; Suzanne E Ohmit; William F Keane; Allan Collins; Shu-Chen Chen; Karren King; Michael J Klag; Donald A Molony; John M Flack Journal: Am J Kidney Dis Date: 2003-07 Impact factor: 8.860
Authors: Claudine T Jurkovitz; Yang Qiu; Changchun Wang; David T Gilbertson; Wendy Weinstock Brown Journal: Am J Kidney Dis Date: 2008-04 Impact factor: 8.860
Authors: V L Burt; J A Cutler; M Higgins; M J Horan; D Labarthe; P Whelton; C Brown; E J Roccella Journal: Hypertension Date: 1995-07 Impact factor: 10.190
Authors: Sri Lekha Tummalapalli; Eric Vittinghoff; Deidra C Crews; Mary Cushman; Orlando M Gutiérrez; Suzanne E Judd; Holly J Kramer; Carmen A Peralta; Delphine S Tuot; Michael G Shlipak; Michelle M Estrella Journal: Am J Nephrol Date: 2020-04-29 Impact factor: 3.754
Authors: Nasrollah Ghahramani; Vernon M Chinchilli; Jennifer L Kraschnewski; Eugene J Lengerich; Christopher N Sciamanna Journal: Kidney Dis (Basel) Date: 2021-03-31
Authors: Adam T Whaley-Connell; Manjula Kurella Tamura; Claudine T Jurkovitz; Mikhail Kosiborod; Peter A McCullough Journal: Am J Kidney Dis Date: 2013-04 Impact factor: 8.860
Authors: Chaoyang Li; Xiao-Jun Wen; Meda E Pavkov; Guixiang Zhao; Lina S Balluz; Earl S Ford; Desmond Williams; Carol A Gotway Journal: Am J Nephrol Date: 2014-04-12 Impact factor: 3.754